Shilpkala completed her Master’s in Pharmacy with specialisation in Pharmaceutics from Indian Institute of Technology, Banaras Hindu University, Varanasi, India (2016). During her graduation she worked on development and ex-vivo evaluation of non-invasive, topical nanoparticulated drug delivery system for the treatment of endophthalmitis. The aim of the project was to enhance the corneal permeation and prolong the drug release. Research outcomes are published in international peer reviewed journal. She has also co-authored 2 other publications.

She was a research associate at Lupin Research Park, Pune, India from 2016 to 2019. During her tenure at Lupin she has worked on design, development and scale up of a range of dosage forms such as oral, ocular and parenteral and successfully completed US FDA filing for oral formulation for Hepatitis B.

Currently, she is pursing Ph.D. at Queen’s University Belfast, UK her research is funded by Marie Sklodowska Curie fellowship. Her research is mostly focused on the minimally invasive and sustain release dosage forms for the treatment of vision threatening diseases such as age related macular degeneration and diabetic retinopathy. She is working on biodegradable microneedles and hydrogels-based systems for intrascleral delivery of anti-vascular endothelial growth factors.